Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Diabetic HFpEF (CARDIA-STIFF)
NCT04739215Phase 4Unknown
- Sponsor
- Gregorio Marañón University General Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Gregorio Marañón University General Hospital. Primary endpoints: Left Ventricular Stiffness Constant (S+) at Peak Exercise at 12 months and Serum Levels of Procollagen Type I C-terminal Propeptide at 12 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04739215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739215.